The Phase 4 EARNEST study met its primary efficacy endpoint of remission of chronic or recurrent pouchitis at Week 14, with 31% of participants receiving vedolizumab achieving remission versus 10%… Read More
Equity proceeds of CA$22M+ raised during 2022 fiscal year Phase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoing Phase 1b/2a clinical trial of… Read More
TORONTO, ON — The Gairdner Foundation is pleased to announce the 2023 Canada Gairdner Award laureates, recognizing some of the world’s most significant biomedical and global health research and discoveries…. Read More
VANCOUVER, BC – Gandeeva Therapeutics, Inc., a precision medicine company focused on designing and developing novel therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, announced today the initiation… Read More
VANCOUVER, BC — SignalChem Lifesciences Corp. today announced that it has received US Food and Drug Administration (FDA) Clearance of Investigational New Drug (IND) Application for its single-arm, open-label, phase… Read More
